Table 4. Allele Distribution as a Function of Age and Ischemic Heart Disease

Genotype (n) Total C-Allele (n) TT TC CC Frequency x2 Fisher Exact Test p Values Group 1 (70–79 y) IHD1 28 4 20 4 0.500 2.19 0.36 NS IHD2 15 5 8 2 0.400 — — — Group 2 (80–89 y) IHD1 27 2 21 4 0.537 3.81 0.15 NS IHD2 25 4 13 8 0.580 — — — Group 3 (90–106 y) IHD1 34 2 21 11 0.632 0.51 0.69 NS IHD2 8 1 5 2 0.562 — — — Total groups 11213 IHD1 89 8 62 19 0.562 4.68 0.11 NS IHD2 48 10 26 12 0.521 — — —

Notes: IHD 5 ischemic heart disease; NS 5 not significant; 1 5 presence of IHD; 2 5 absence of IHD. p values were tested using x2 test (value shown) and two- Fisher exact test (probability shown) in groups 1–3 for IHD1 vs IHD2 subgroups.

metabolic abnormalities—the role of insulin resistance and the sym- pathoadrenal system. N Engl J Med.

;

:

–

Sechi LA, Bartoli E. Molecular mechanisms of insulin resistance in ar- terial hypertension. Blood Pressure.

;

(suppl

):

–

Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymor- phic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol.

;

:

–

Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variants associated with variation in plasma lipo- proteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol.

;

:

–

Groenendijk M, Cantor RM, Blom NH, Rotter JI. de Bruin TW, Dallinga-Thie GM. Association of plasma lipids and apolipoproteins with the insulin response element in the ap

-III promoter region in familial combined hyperlipidemia. J Lipid Res.

;

:

–

Hoffer MJ, Sijbrands EJ, de Man FH, Havekes LM, Smelt AH, Frants RR. Increased risk for endogenous hypertrigliceridemia is associated with an apolipoprotein C

haplotype specified by the Ss

polymor- phism. Eur J Clin Invest.

;

:

–

Rees A, Stocks J, Paul H, Ohuchi Y, Galton D. Haplotypes identified by DNA polymorphisms at the apolipoprotein A-

and C-III loci and hypertriglyceridaemia. A study in a Japanese population. Hum Genet.

;

:

–

Price WH, Morris SW, Kitchin AH, Wenham PR, Burgon PR, Donald PM. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet.

;

:

–

Skobeleva NA, Vasina VI, Volkova MV, et al. DNA polymorphism in the region of APOB

, APOCIII, APOE, and angiotensin-converting enzyme genes and indicators of the lipid spectrum in children and ado- lescents in St. Petersburg. Mol Gen Mikrobiol Virusol.

;

:

–

Price WH, Morris SW, Burgon R, Donald PM, Kitchin AH. Apolipo- protein CIII polymorphism and coronary heart disease. Lancet.

;

:

Sambrook J, Fritsch EF. Analysis and cloning of eukaryotic genomic DNA. In: Maniatis R, ed. Molecular Cloning: A Laboratory Manual.

nd ed. New York: Cold Spring Harbor Laboratory Press;

:

–

Esterbauer H, Hell E, Krempler F, Patsch W. Allele-specific differ- ences in apolipoprotein C-III

NA expression in human liver. Clin Chem.

;

:

–

Broitman SA, Cerda S, Wilkinson J

th. Cholesterol metabolism and colon cancer. Prog Food Nutr Sci.

;

:

–

Tulinius H, Sigfusson N, Sigvaldason H, Bjardnadottir K, Tryggvadot- tir L. Risk factors for malignant diseases: a cohort study on a population of

,

Icelanders. Cancer Epidemiol Biomarkers Prev.

;

:

–

O’Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev.

;

:

–

Vaupel JW, Carey JR, Christensen K, et al. Biodemographic trajecto- ries of longevity. Science.

;

:

–

Yashin AI, De Benedictis G, Vaupel JW, et al. Genes, demography, and life span: the contribution of demographic data in genetic studies on aging and longevity. Am J Hum Genet.

;

:

–

Surguchov AP, Liu S-B, Patsch W. Simple non-radioactive method of analysis of polymorphic markers flanking human apolipoprotein C-III gene. Disease Markers.

;

:

–

Acknowledgments

We thank Dr. Kenneth Boheler and Dr. Olga Potapova for helpful discus- sions, encouragement, and valuable help in preparing the manuscript, and Frances O’Connor for the valuable help in statistical analysis.

Address correspondence to Sergey V. Anisimov, MD, Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Balti- more, MD 21224. E-mail: anisimovs@grc.nia.nih.gov

References

Krauss RM, Herbert PN, Levy RI, Fredrickson DS. Further observa- tions on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res.

;

:

–

Wang C-S, M

onathy WJ, Kloer HU, Alaupovic P. Modulation of li- poprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest.

;

:

–

Shimada M, Shimano H, Gotoda T, et al. Overexpression of human li- poprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J Biol Chem.

;

:

–

Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted dis- ruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceri- demia. J Biol Chem.

;

:

–

Ito Y, Azrolan N, O’Connell A, Walsh A, Breslow JL. Hypertriglycer- idemia as a result of human apo CIII gene expression in transgenic mice. Science.

;

:

–

Dammerman M, Sandkuijl LA, Halaas JL, Ghung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and

untranslated region polymorphisms. Proc Natl Acad Sci USA.

;

:

–

Shoulders CC, Grantham TT, North JD, et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian schoolchildren. Hum Genet.

;

:

–

Ogami K, Hadzopoulou-Cladaras M, Cladaras C, Zannis VI. Promoter elements and factors required for hepatic and intestinal transcription of the human Ap

III gene. J Biol Chem.

;

:

–